Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.

Ponomarenko DM, Klimova ID, Chapygina YA, Dvornichenko VV, Zhukova NV, Orlova RV, Manikhas GM, Zyryanov AV, Burkhanova LA, Badrtdinova II, Oshchepkov BN, Filippova EV, Orlov SV, Kolesnikov SI, Sufianov AA, Baum SR, Zaitzeva OY, Komissarov AB, Grudinin MP, Kiselev OI, Tsyb AF, Venanzi F, Shcherbinina V, Chursov A, Gabai VL, Shneider AM.

Oncotarget. 2017 Mar 25;8(32):53730-53739. doi: 10.18632/oncotarget.16574. eCollection 2017 Aug 8.

2.

Discovery of a new class of antiviral compounds: camphor imine derivatives.

Sokolova AS, Yarovaya OI, Shernyukov AV, Gatilov YV, Razumova YV, Zarubaev VV, Tretiak TS, Pokrovsky AG, Kiselev OI, Salakhutdinov NF.

Eur J Med Chem. 2015 Nov 13;105:263-73. doi: 10.1016/j.ejmech.2015.10.010. Epub 2015 Oct 22.

PMID:
26498572
3.

Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

Tsybalova LM, Stepanova LA, Kuprianov VV, Blokhina EA, Potapchuk MV, Korotkov AV, Gorshkov AN, Kasyanenko MA, Ravin NV, Kiselev OI.

Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11.

PMID:
25976545
4.

Glycyrrhizic acid derivatives as influenza A/H1N1 virus inhibitors.

Baltina LA, Zarubaev VV, Baltina LA, Orshanskaya IA, Fairushina AI, Kiselev OI, Yunusov MS.

Bioorg Med Chem Lett. 2015 Apr 15;25(8):1742-1746. doi: 10.1016/j.bmcl.2015.02.074. Epub 2015 Mar 7.

PMID:
25801933
5.

Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI.

PLoS One. 2015 Mar 23;10(3):e0119520. doi: 10.1371/journal.pone.0119520. eCollection 2015.

6.

Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus.

Shtro AA, Zarubaev VV, Luzina OA, Sokolov DN, Kiselev OI, Salakhutdinov NF.

Bioorg Med Chem. 2014 Dec 15;22(24):6826-36. doi: 10.1016/j.bmc.2014.10.033. Epub 2014 Oct 31.

PMID:
25464881
7.

Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.

Sokolova AS, Yarovaya OC, Korchagina DV, Zarubaev VV, Tretiak TS, Anfimov PM, Kiselev OI, Salakhutdinov NF.

Bioorg Med Chem. 2014 Apr 1;22(7):2141-8. doi: 10.1016/j.bmc.2014.02.038. Epub 2014 Mar 1.

PMID:
24631360
8.

Structural Features of the Peptide Homologous to 6-25 Fragment of Influenza A PB1 Protein.

Egorov VV, Matusevich OV, Shaldzhyan AA, Skvortsov AN, Zabrodskaya YA, Garmay YP, Landa SB, Lebedev DV, Zarubayev VV, Sirotkin AK, Vasin AV, Kiselev OI.

Int J Pept. 2013;2013:370832. doi: 10.1155/2013/370832. Epub 2013 Dec 24.

9.

New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.

Sokolova AS, Yarovaya CO, Shernyukov CA, Pokrovsky CE, Pokrovsky CA, Lavrinenko VA, Zarubaev VV, Tretiak TS, Anfimov PM, Kiselev OI, Beklemishev AB, Salakhutdinov NF.

Bioorg Med Chem. 2013 Nov 1;21(21):6690-8. doi: 10.1016/j.bmc.2013.08.014. Epub 2013 Aug 12.

PMID:
23993669
10.

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.

Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26.

11.

Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.

Petukhova NV, Gasanova TV, Stepanova LA, Rusova OA, Potapchuk MV, Korotkov AV, Skurat EV, Tsybalova LM, Kiselev OI, Ivanov PA, Atabekov JG.

Curr Pharm Des. 2013;19(31):5587-600.

PMID:
23394564
12.

The use of transient expression systems for the rapid production of virus-like particles in plants.

Thuenemann EC, Lenzi P, Love AJ, Taliansky M, Bécares M, Zuñiga S, Enjuanes L, Zahmanova GG, Minkov IN, Matić S, Noris E, Meyers A, Hattingh A, Rybicki EP, Kiselev OI, Ravin NV, Eldarov MA, Skryabin KG, Lomonossoff GP.

Curr Pharm Des. 2013;19(31):5564-73. Review.

PMID:
23394559
13.

Transmission studies resume for avian flu.

Fouchier RA, García-Sastre A, Kawaoka Y, Barclay WS, Bouvier NM, Brown IH, Capua I, Chen H, Compans RW, Couch RB, Cox NJ, Doherty PC, Donis RO, Feldmann H, Guan Y, Katz JM, Kiselev OI, Klenk HD, Kobinger G, Liu J, Liu X, Lowen A, Mettenleiter TC, Osterhaus AD, Palese P, Peiris JS, Perez DR, Richt JA, Schultz-Cherry S, Steel J, Subbarao K, Swayne DE, Takimoto T, Tashiro M, Taubenberger JK, Thomas PG, Tripp RA, Tumpey TM, Webby RJ, Webster RG.

Science. 2013 Feb 1;339(6119):520-1. doi: 10.1126/science.1235140. Epub 2013 Jan 23. No abstract available.

14.

Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.

Sokolov DN, Zarubaev VV, Shtro AA, Polovinka MP, Luzina OA, Komarova NI, Salakhutdinov NF, Kiselev OI.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7060-4. doi: 10.1016/j.bmcl.2012.09.084. Epub 2012 Oct 4.

PMID:
23099095
15.

A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles.

Blokhina EA, Kuprianov VV, Stepanova LA, Tsybalova LM, Kiselev OI, Ravin NV, Skryabin KG.

Virology. 2013 Jan 20;435(2):293-300. doi: 10.1016/j.virol.2012.09.014. Epub 2012 Oct 11.

16.

Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments.

Zarubaev VV, Garshinina AV, Kalinina NA, Shtro AA, Belyaevskaya SV, Slita AV, Nebolsin VE, Kiselev OI.

Pharmaceuticals (Basel). 2011 Nov 25;4(12):1518-1534.

17.

Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.

WHO Writing Group, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Zhang W.

Influenza Other Respir Viruses. 2012 Mar;6(2):142-52, e1-5. doi: 10.1111/j.1750-2659.2011.00277.x. Epub 2011 Aug 8.

18.

Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus.

Zarubaev VV, Golod EL, Anfimov PM, Shtro AA, Saraev VV, Gavrilov AS, Logvinov AV, Kiselev OI.

Bioorg Med Chem. 2010 Jan 15;18(2):839-48. doi: 10.1016/j.bmc.2009.11.047. Epub 2009 Nov 29.

PMID:
20006516
19.

Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects.

Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd.

Eur Heart J. 2007 May;28(10):1205-10. Epub 2007 Apr 17.

PMID:
17440221
20.

Photodynamic inactivation of influenza virus with fullerene C60 suspension in allantoic fluid.

Zarubaev VV, Belousova IM, Kiselev OI, Piotrovsky LB, Anfimov PM, Krisko TC, Muraviova TD, Rylkov VV, Starodubzev AM, Sirotkin AC.

Photodiagnosis Photodyn Ther. 2007 Mar;4(1):31-5. doi: 10.1016/j.pdpdt.2006.08.003. Epub 2006 Oct 6.

PMID:
25047188

Supplemental Content

Loading ...
Support Center